|
 |
|
|||||||
|
|||||||||
© 2001 by the American Diabetes Association, Inc.
Epidermal Growth Factor Increases Undifferentiated Pancreatic Embryonic Cells In Vitro
A Balance Between Proliferation and Differentiation
INSERM U457, Hospital R. Debré, Paris, France
During embryonic life, the development of a proper mass of mature pancreatic tissue is thought to require the proliferation of precursor cells, followed by their differentiation into endocrine or acinar cells. We investigated whether perturbing the proliferation of precursor cells in vitro could modify the final mass of endocrine tissue that develops. For that purpose, we used activators or inhibitors of signals mediated by receptor tyrosine kinases. We demonstrated that when embryonic day 13.5 rat pancreatic epithelium is cultured in the presence of PD98059, an inhibitor of the mitogen-activated protein (MAP) kinase, epithelial cell proliferation is decreased, whereas endocrine cell differentiation is activated. On the other hand, in the presence of epidermal growth factor (EGF), an activator of the MAP kinase pathway, the mass of tissue that develops is increased, whereas the absolute number of endocrine cells that develops is decreased. Under this last condition, a large number of epithelial cells proliferate but remain undifferentiated. In a second step, when EGF is removed from the pool of immature pancreatic epithelial cells, the cells differentiate en masse into insulin-expressing cells. The total number of insulin-expressing cells that develop can thus be increased by first activating the proliferation of immature epithelial cells with growth factors, thus allowing an increase in the pool of precursor cells, and next allowing their differentiation into endocrine cells by removing the growth factor. This strategy suggests a possible tissue engineering approach to expanding ß-cells.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Luo, N. Yano, and J. Z. Q. Luo The molecular mechanism of EGF receptor activation in pancreatic beta-cells by thyrotropin-releasing hormone Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E889 - E899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Murtaugh, A. C. Law, Y. Dor, and D. A. Melton {beta}-Catenin is essential for pancreatic acinar but not islet development Development, November 1, 2005; 132(21): 4663 - 4674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. Suarez-Pinzon, Y. Yan, R. Power, S. J. Brand, and A. Rabinovitch Combination Therapy With Epidermal Growth Factor and Gastrin Increases {beta}-Cell Mass and Reverses Hyperglycemia in Diabetic NOD Mice Diabetes, September 1, 2005; 54(9): 2596 - 2601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. Suarez-Pinzon, J. R. T. Lakey, S. J. Brand, and A. Rabinovitch Combination Therapy with Epidermal Growth Factor and Gastrin Induces Neogenesis of Human Islet {beta}-Cells from Pancreatic Duct Cells and an Increase in Functional {beta}-Cell Mass J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3401 - 3409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A G Kayali, A Stotland, K V Gunst, M Kritzik, G Liu, S Dabernat, Y-Q Zhang, W Wu, and N Sarvetnick Growth factor-induced signaling of the pancreatic epithelium J. Endocrinol., April 1, 2005; 185(1): 45 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ogata, L. Li, S. Yamada, Y. Yamamoto, Y. Tanaka, I. Takei, K. Umezawa, and I. Kojima Promotion of {beta}-Cell Differentiation by Conophylline in Fetal and Neonatal Rat Pancreas Diabetes, October 1, 2004; 53(10): 2596 - 2602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Saito, S. Okada, K. Ohshima, E. Yamada, M. Sato, Y. Uehara, H. Shimizu, J. E. Pessin, and M. Mori Differential Activation of Epidermal Growth Factor (EGF) Receptor Downstream Signaling Pathways by Betacellulin and EGF Endocrinology, September 1, 2004; 145(9): 4232 - 4243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, M. M.W. Chong, R. Darwiche, H. E. Thomas, and T. W.H. Kay Severe Pancreatitis with Exocrine Destruction and Increased Islet Neogenesis in Mice with Suppressor of Cytokine Signaling-1 Deficiency Am. J. Pathol., September 1, 2004; 165(3): 913 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Suzuki, H. Nakauchi, and H. Taniguchi Prospective Isolation of Multipotent Pancreatic Progenitors Using Flow-Cytometric Cell Sorting Diabetes, August 1, 2004; 53(8): 2143 - 2152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Zhang, M. Hosaka, Y. Sawada, S. Torii, S. Mizutani, M. Ogata, T. Izumi, and T. Takeuchi Parathyroid Hormone-Related Protein Induces Insulin Expression Through Activation of MAP Kinase-Specific Phosphatase-1 That Dephosphorylates c-Jun NH2-Terminal Kinase in Pancreatic {beta}-Cells Diabetes, November 1, 2003; 52(11): 2720 - 2730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Duvillie, M. Attali, V. Aiello, E. Quemeneur, and R. Scharfmann Label-Retaining Cells in the Rat Pancreas: Location and Differentiation Potential in Vitro Diabetes, August 1, 2003; 52(8): 2035 - 2042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rachdi, J.-C. Marie, and R. Scharfmann Role for VPAC2 Receptor-Mediated Signals in Pancreas Development Diabetes, January 1, 2003; 52(1): 85 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Buteau, S. Foisy, E. Joly, and M. Prentki Glucagon-Like Peptide 1 Induces Pancreatic {beta}-Cell Proliferation Via Transactivation of the Epidermal Growth Factor Receptor Diabetes, January 1, 2003; 52(1): 124 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-A. Huotari, P. J. Miettinen, J. Palgi, T. Koivisto, J. Ustinov, D. Harari, Y. Yarden, and T. Otonkoski ErbB Signaling Regulates Lineage Determination of Developing Pancreatic Islet Cells in Embryonic Organ Culture Endocrinology, November 1, 2002; 143(11): 4437 - 4446. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |